| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
To evaluate human cancer stem cells in xenotransplant models, a variety of immunodeficient mouse lines have been developed. We found that in xenograft engraftment, inhibition of phagocytic reaction of mouse macrophages is essential in addition to lymphoid depletion. Murine signal regulatory protein alpha (mSIRPA) on macrophages cannot bind to human CD47 (hCD47), resulting phagocytic reaction against human cells. Here, we have established a new immunodeficient BRGhS mouse line, B6.Rag2(null)Il2rg(null), harboring a complete macrophage tolerance. BRGhS mouse line was introduced by human SIRPA, which allows to bind human CD47, resulting in inhibition of phagocytosis against human cell graft. BRGhS strain should be very useful in future xenotransplant experiments of human cancer stem cells.
|
